topic
stringlengths 245
1.29k
| doc
stringlengths 52
16.9k
| label
stringclasses 3
values |
|---|---|---|
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 40.0-75.0, Parkinson Disease Parkinson disease diagnosed by United Kingdom Parkinson's disease Society Brain Bank Postural instability and gait disturbance phenotype Hoehn and Yahr stage ≤ 3 Mini-Mental status examination ≥ 24 Significant motor complication affecting daily activities Drugs related to acetylcholine metabolism | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 50.0-85.0, PD Gait Dysfunction, Neurologic Rehabilitation Diagnosis of "probable" idiopathic Parkinson's disease according to Gelb et al (Gelb, 1999) Mild to moderate stage of disease (stage 2-3) according to Hoehn & Yahr scale Ability to walk on treadmill Visual and hearing capacity sufficient to perceive the cues No cognitive impairment (Mini-Mental State Examination score ≥ 26) Stable pharmacological treatment since 2 weeks before admission and during rehabilitation Diagnosis of atypical or vascular Parkinsonism Occurrence of cardiovascular, orthopaedic, peripheral nerves, musculoskeletal and vestibular disorders which could affect patient's locomotion or balance Neuropsychiatric disturbances Severe dyskinesia Severe freezing of gait | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Vitiligo Diagnosis of non-segmental vitiligo affecting at least 10% of BSA since at least 3 months Patient requiring a treatment by UVB For both female of childbearing potential and male patients: Use of an effective contraceptive method during the study period (see Annex 5 for details) Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted Able to adhere to the study visit schedule and other protocol requirements Patient registered to the French Social Security Segmental or mixed vitiligo 2. Other than vitiligo, history of any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease. 3. Any condition which would place the subject at unacceptable risk if he/she were to participate in the study. 4. Any condition that confounds the ability to interpret data from the study. 5. Pregnant or breast feeding, pregnancy urinary tests will be performed (see Annex 5 for details about pregnancy testing and contraception) 6. History of allergy to any component of apremilast 7. History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease) 8. Active substance abuse or a history of substance abuse within 6 months prior to Screening 9. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed at least 4 weeks prior to Screening. 10. Malignancy or history of malignancy (except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence) 11. Evidence of skin conditions that would interfere with clinical assessments 12. Topical therapy within 2 weeks of randomization 13. Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources 14. Prior treatment with apremilast 15. Use of phototherapy within 4 weeks prior to randomization (ie, UVB, PUVA) 16. Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, 17. Patients assessed to be uncooperative 18. Participants in other clinical studies 19. Vulnerable people: pregnant or breast-feeding women (an urinary pregnancy test will be realized in every visit), minors, adults under guardianship or guardianship, deprived of freedom 20. Patient with a rare hereditary disease such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome 21. Patient with severe renal insufficiency | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 45.0-999.0, Parkinson Disease Presence of Parkinson's disease. PD diagnosis following the UK Parkinson's Disease Society Brain Bank Research Center (UKPDSBRC) clinical diagnostic for PD, consistent with the typical nigrostriatal denervation pattern on VMAT2 Hoehn and Yahr stages 2-4 and/or presence of PIGD features, such as history of (near) falls, slow gait, and/or freezing of gait Available space to place table in their home (approximately 6 ft x 5 ft area) Inability to stand or walk without an assistive device History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain History of significant symptomatic cardiovascular or pulmonary disease History of active symptomatic rheumatic arthritis History of stroke or other focal brain conditions with residual sensorimotor deficits interfering with stance functions History of chronic pain syndrome requiring daily narcotic analgesics Evidence of dementia Venous stasis or severe varicosities | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 45.0-85.0, Parkinson Disease Age 45 to 85 Diagnosis of Parkinson's Disease using the UK Brain Bank Fine motor impairments (if available, scores 2 and higher on the UPDRS motor examination part III.23 and 24) Medication stable for at least 30 days Features suggestive of other causes of parkinsonism, including cerebrovascular disease or history of major head trauma Inability to move fingers or hands Hoehn and Yahr stage 4 and higher Ferrous metal implants which may interfere with the MEG data acquisition and/or be an MRI safety concern Dementia Participants engaged in other research studies involving music therapies Participants whose insurance does not cover Occupational Therapy costs or who have no insurance | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 45.0-60.0, Stroke Patients' age ranged from 45-60 years old Normal body weight with a body mass index (BMI) ranged from 18.5 to 24.9 kg/m2 Patients' had the ability to maintain sitting position without using any aids Patients' had the ability to stand from sitting five times independently Cooperative patients with ability to understand instructions and follow simple verbal commands The duration of illness was from six months to 2 years The degree of the paretic lower limb spasticity ranged between (1:1+) according to the Modified Ashworth Scale The degree of the paretic lower limb weakness was not less than grade 3 according to group muscle testing History of previous strokes and other neurological disorders Visual, auditory and vestibular deficits Cognitive impairments and language deficits Leg length discrepancy is more than 0.5 cm Previous history of orthopedic conditions in back or lower limbs (e.g. low back pain, fractures, deformities and surgeries) | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 20.0-999.0, Stroke Motor Disorders Cortical stroke (study group) hemiparesis sensory aphasia complete arm paralysis unilateral neglect other neurological disease (PD, Alzheimer) | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 7.0-25.0, Dystonia Ability to give informed consent or assent for the study 2. Dystonia symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical 3. Age 7-25 4. Stable doses of anti-dystonia medications (such as levodopa, baclofen, or diazepam) for at least 30 days prior to baseline assessment 5. If patient receives botulinum toxin injections, patient should be on a stable injection regimen 6. Intact thalamic anatomy as determined by standard clinical MRI Pregnancy or breast feeding 2. Major comorbidity increasing the risk of surgery (severe hypertension, severe diabetes, or need for chronic anticoagulation other than aspirin) 3. Inability to comply with study follow-up visits 4. Any prior intracranial surgery 5. Uncontrolled epilepsy 6. Immunocompromised 7. Has an active infection 8. Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) to treat a chronic condition 9. Has an existing implanted neurostimulator or cardiac pacemaker. 10. Dystonia caused by known genetic mutation in any DYT genes | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-70.0, Crohn Disease Ulcerative Colitis Intestinal Helminthiasis The included volunteer is a researcher within parasitology with main focus on Trichuris trichiura and Trichiura suis. He planned to infect himself and contacted our department with the purpose of being monitored during this infection for safety (medical supervision) and research reasons. The only clinical criterion for his in the study was that he was healthy | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 19.0-999.0, Hypertension and Hyperlipidemia Both man and woman who is over 19 years old Patient with dyslipidemia and hypertension sSBP difference is ≥20 mmHg or sDBP difference is ≥10 mmHg A history of cardiovascular disease Rhabdomyolysis, myopathy Hypertension or hypercholesterolemia due to secondary causes Uncontrolled diabetes Evidence of hepatic or renal disease | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 0.0-999.0, Parkinson Disease Individuals with Parkinson's disease (including multiple system atrophy). Males and females are eligible for the study. Appendectomized cohort must have had their appendectomy at least 20 years before Parkinson's disease onset Body Mass Index greater than or equal to 35 or less than or equal to 18. 2. Vital signs outside of acceptable range at Screening Visit, i.e., blood pressure >160/100, oral temperature >100°F, pulse >100. 3. Use of any of the following drugs within the last 6 months systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular, or oral) cytokines methotrexate or immunosuppressive cytotoxic agents large doses of commercial probiotics consumed (greater than or equal to 108 cfu or organisms per day) includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, foods do not apply. 4. Acute viral/bacterial infection disease at the time of sampling (defer sampling until subject recovers). Acute disease is defined as the presence of a moderate or severe illness with or without fever. 5. Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet. 6. Recent history of chronic alcohol consumption defined as more than five 1.5- ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day. 7. Positive test for HIV, HBV or HCV. 8. Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired) including HIV infection. 9. Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time. 10. History of active uncontrolled gastrointestinal disorders or diseases including inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis irritable bowel syndrome (IBS) (moderate-severe) persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated); 11. Female who is pregnant or lactating. 12. Atypical or secondary Parkinson's disease 13. Adults that are unable to consent, individuals that are not yet adults and prisoners are not eligible for this study | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 33.0-72.0, Parkinson Disease Apathy patients who participated in "Non Motors Aspects in De Novo Parkinson's Disease (Honeymoon)" NCT02786667 Patients under dopaminergic treatment, with stable dopaminergic treatment for at least 2 months Patients with medical insurance signed informed consent diagnosis other than Parkinson's Disease dementia (Mattis <130) patients protected by law (i.e. pregnant or parturient women) | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-85.0, Neuro-Degenerative Disease Age between 18 and 85 years of age Participants must have undergone implantation of DBS electrodes Participants must be able to understand the purpose of this research and must sign the informed consent form Participants must understand that the role of this research is to enhance our understanding of brain functioning and that he/she will not directly or indirectly benefit from the study Participants who have serious cognitive or psychological impairments and cannot give informed consent Participants who are unable to effectively or efficiently communicate, for example patients suffering from speech deficits (dysarthria, aphasia) or are non-English speaking | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Dementia Age >18y Dementia (Alzheimer type and mixed type) Informed consent signed by the patient or his legal representative Mini Mental State Examination ≤ 26 Other forms of dementia Inflammatory bowel diseases Liver cirrhosis Antibiotic treatment within the last 14 days Any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol Healthy controls Age >18y Informed consent No known acute or chronic illness | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 50.0-86.0, Alzheimer's Disease Assessment of safety and exploratory treatment efficacy in subjects who were enrolled and completed phase 1/2a clinical trial of Subjects who have been treated with either or placebo at least 12 months ago Subjects who voluntarily decided to participate and signed the consent form after receiving explanations on the clinical trial (in case it is difficult for the participant to sign, the consent of the legal representative) Subjects who were not enrolled in phase 1/2a clinical trial of Neurostem® for assessing safety and exploratory treatment efficacy Other subjects, excluding those listed above, who were deemed unsuitable by the PI | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-80.0, Parkinson Disease A diagnosis of idiopathic Parkinson's disease, with bilateral symptoms at Hoehn and Yahr Stage greater than or equal to II. 2. Documented improvement in motor signs on versus off dopaminergic medication, with a change in the Unified Parkinson's Disease Rating Scale motor (UPDRS III) score of >= 30% off to on medication. 3. The presence of complications of medication such as wearing off signs,fluctuating responses and/or dyskinesias, and/or medication refractory tremor,and/or impairment in the quality of life on or off medication due to these factors. 4. Subjects should be on stable doses of medications, which should remain unchanged until the DBS system is activated. After the DBS system is optimized(during which time the overall medication dose may be reduced to avoid discomfort and complications such as dyskinesias) the medication dose should remain unchanged, if possible, for the duration of the study. 5. Treatment with carbidopa/levodopa, and with a dopamine agonist at the maximal tolerated doses as determined by a movement disorders neurologist. 6. Ability and willingness to return for study visits, at the initial programming and after three, six and twelve months of DBS. 7. Age > 18 8. Has a history of and/or displays freezing of gait Subjects with significant cognitive impairment and/or dementia as determined bya standardized neuropsychological battery. 2. Subjects with clinically active depression, defined according to the Diagnostic and Statistical manual of Mental Disorders, Fourth Edition (DSM-IV) and as scored on a validated depression assessment scale. 3. Subjects with very advanced Parkinson's disease, Hoehn and Yahr stage 5 on medication (non-ambulatory). 4. Age > 80. 5. Subjects with an implanted electronic device such as a neurostimulator, cardiac pacemaker/defibrillator or medication pump. 6. Subjects, who are pregnant, are capable of becoming pregnant, or who are breast feeding. 7. Patients with cortical atrophy out of proportion to age or focal brain lesions that could indicate a non-idiopathic movement disorder as determined by MRI 8. Subjects having a major comorbidity increasing the risk of surgery (prior stroke,severe hypertension, severe diabetes, or need for chronic anti-coagulation other than aspirin). 9. Subjects having any prior intracranial surgery. 10. Subjects with a history of seizures. 11. Subjects, who are immunocompromised. 12. Subjects with an active infection. 13. Subjects, who require diathermy, electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS) to treat a chronic condition. 14. Subjects, who have an inability to comply with study follow-up visits or study protocol. 15. Subjects, who are unable to understand or sign the informed consent | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 40.0-85.0, Parkinson Disease .Parkinson's disease diagnosis, Hoehn-Yahr level I-III 2. .Stable medicine intake for 2 weeks at least 3. .Able to walk independently for 15 meters 4. .Aged 40-85 years old .Cognition deficits(MMSE score<24) 2. .Combined other neurological disease, such as stork, SCI, and so on. 3. .Pregnant or Breastfeeding | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-80.0, Breast Cancer Prostate Cancer Lung Cancer Colorectal Cancer Cervical Cancer Oral Cancer A cancer survivor of breast, prostate, lung, colorectal, cervical or oral cancer survivor and live within the Baltimore Maryland area Finished your active cancer treatment at least three months ago Overweight or obese and do not exercise daily Do not have any physical limitation to do mild to moderate physical activities Have a smart phone (iPhone or Android device) with Wi-Fi internet connection at home Actively using an email account Willing to accept the random study assignment Willing to wear a Fitbit band 'a physical activity tracking device' on your wrist for five weeks every single day Willing to have an Echo speaker 'a smart home speaker with voice assistant' installed in your home and use the digital voice assist for four weeks Willing to receive daily text messages on your phone for four weeks Already doing moderate to high physical activities in their daily life (rapid screener) Planning to relocate within the next 4-5 weeks Stage 4 cancer Already using physical activity tracker or part of a physical activity program Part of another study that may interfere with our outcome of interest, unstable mental condition Mental condition that prevents patient from performing the study activities and requirements Pregnancy | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson Disease self-reported diagnosis of Parkinson's disease age 18 years or over Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III> 57 Montreal Cognitive Assessment (MOCA)<21 not being able to wear or operate Google Glass | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 0.0-999.0, Fall Having had a Falls and Bone Health Assessment by the Integrated Falls and Bone Health Service (IF & BHS) Wandsworth Having falls or bone health risk factors but being able to mobilise without walking aids Having been assessed by IF & BHS as having capacity to take part in a gardening intervention programme Having indicated an interest in attending a gardening group following the IF & BHS assessment if they a) do not want to participate in any other elements of the IF & BHS programme or if they b) have completed other elements of the service offered by the IF & BHS, e.g. exercise groups, Nordic walking or Zumba gold Having a known diagnosis of dementia Not being able to adequately understand verbal explanations or written information given in English Having a falls risk profile that indicates that the individual has high falls risk in this context this is a clinical decision and will take account of a number of variables including mobility (Timed up & Go of more than 20 sec) and their general health (e.g., large postural drop, uncontrolled diabetes, significant behaviour that challenges) | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-85.0, Parkinson Disease Neurogenic Orthostatic Hypotension Idiopathic Parkinson's disease patients with orthostatic hypotension (Systolic Blood Pressure drop of > 20 mm hg or Diastolic Blood Pressure drop of >10 mm hg measured at some point) within a month of inclusion Age >85 Concurrent use of Midodrine Medical conditions that in the opinion of the investigator, might not allow for same completion of the study i.e. unstable angina, neoplasm, etc | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-75.0, Parkinson Disease Idiopathic Parkinson's disease Disease duration longer than 15 years Had STN deep brain stimulation implant more than 10 years Available and willing to be followed-up according to study protocol Patients with serious diseases such as tumor, sever liver or kidney dysfunction were not selected in the clinical trials Epilepsy Pregnant female History of severe neuropsychiatric disease Patients are taking part in other clinical trials in recent several months | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Benign Paroxysmal Positional Vertigo patients who have had symptoms of vertigo for at least 1 week duration patients with a documented positive Dix-Hallpike test on referral patients with intact cognitive function and had the ability to communicate and understand instructions to perform a home-based exercise patients with history of prior ear surgery patients with orthopaedic or connective tissue disorder that impairs functional neck or trunk range of motion patients with a significant neurological disorder or spinal cord damage, and patients who have been prescribed with home-based exercises for BPPV | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 30.0-100.0, Significant Prostate Cancer Urine Metabolomics Cancer Screening Subjects who have planned to undergo prostate biopsy. 2. Subjects who are aged between 30 and 100 years men. 3. For subjects who are prostate cancer patients for rebiopsy, the testosterone level should be within normal limit (testosterone >1.5 ng/ml). 4. Subjects who understand the entire study procedures and consent to donate his spot urine (once for 50 ml) and agree with subsequent analyses of his clinical information including biopsy results, treatments and outcomes. (Note: Subjects will be told that the urine metabolomics results will not be revealed to them.) Subjects who have other active cancers. However, subjects who have cancers that have been curatively treated and who are disease-free for 3 years or longer are allowed to be enrolled. 2. Subjects who have severe organ function impairment which may significantly alter general cell metabolism determined by the investigators, such as or Cre > 3.0, HbA1c > 9.0%, symptomatic heart failure, or other symptomatic metabolic diseases. 3. Subjects who are receiving or have received systemic therapy, such as chemotherapy, androgen deprivation therapy (ADT), immunotherapy, or targeted therapy within 3 months of the screening. 4. Subjects who have been treated with pelvic radiotherapy within 3 months of the screening. 5. Subjects who have significant infection or inflammation within 8 weeks of the biopsy. 6. Subjects who have pyuria (defined as > 5 WBC/HPF) of urinalysis results within 4 weeks of the biopsy 7. Topical or oral prednisolone equivalent dosage larger 10 mg per day for 14 days or more. 8. The last dose of prednisolone is within 4 weeks of the biopsy. 9. Subjects who have a life expectancy less than 12 months. 10. Subjects who use MCS or found supplementation containing large amount of lycopene in recent 60 days or less. The definition of large amount of lycopene is more than 2 mg per day | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Schizophrenia Spectrum and Other Psychotic Disorders he/she currently uses CLZ or he/she has used CLZ in the past/will use CLZ he/she has received a diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS his/her age must be ≥18 years old he/she must be able to speak and read the language of the Informed Consent (differs per country) he/she must be mentally competent and have decisional capacity with regard to a decision to participate in the current study admission to a psychiatric unit involuntarily (not all countries) a history of Parkinson's disease | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 21.0-99.0, Parkinson Disease unimpaired controls and 30 subjects with Parkinson's Disease (described in detail below see inclusion/ ). The 30 subjects with Parkinson's Disease will be assigned into 3 groups (10 with H&Y Stage 1, 10 with H&Y Stage 2, and 10 with H&Y Stage 3) Individuals with a diagnosis of Parkinson's Disease (made by movement disorders specialist) will be included in this study. Additional self-reported ability to walk >10 m overground as well as walk on a treadmill for a total of 14 minutes with rest breaks as needed, and be classified as Stage 1, 2, or 3 on the Hoehn and Yahr Scale since these stages have the most independence with mobility (Goetz et. al, 2004) Hoehn and Yahr Stage 4 and 5, uncontrolled cardiorespiratory/metabolic disease (e.g., cardiac arrhythmia, uncontrolled hypertension or diabetes, orthostatic hypertension, chronic emphysema), or other neurological or orthopedic disorders that may affect walking. The investigators will also participants with severe communication impairments, which could impede understanding of the purpose or procedures of the study or an inability to comply with experimental procedures | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 0.0-999.0, Velopharyngeal Insufficiency Patients must have border line velopharyngeal abnormality which was diagnosed clinically. Ability to understand and the willingness to sign a written informed consent(if he was a child so his parents or his guardian should has tis ability) Mental Retardation. 2. Presence of Neurological deficit affecting speech. 3. Palatal paralysis or paresis. 4. Overt cleft palate | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 19.0-999.0, Cardiovascular Diseases Neuro-Degenerative Disease Cancer Pregnancy Men and women Older than 18 years Cardiovascular disease neurodegenerative disease Cancer Pregnancy Inability to understand and to want Refusal to sign the informed consent | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-80.0, Tremor Men and women, between 18 and 80 years Patients who underwent the MRgFUS procedure Patients who are able and willing to give consent and able to attend all study visits and Radiologic follow-up examination by MRI A diagnosis of ET or Idiopathic PD as confirmed from clinical history and examination preformed by a movement disorders neurologist ET patients: tremor severity score of greater than or equal to 2 in the treated hand/arm as measured by postural or action item on the Clinical Rating Scale for Tremor (CRST) PD patients: tremor severity score of equal or greater than 3 on either item 20 or item 21 of motor part in the Unified PD Rating Scale (UPDRS) Substantial disability in the performance of at least two daily activities from the disability subsection of the scales UPDRS for PD patients or CRST for ET patients The patient must have a history of an unsatisfactory response to medical management. All patients will need to have tried and failed at least one drug. Alternatively, a patient may also qualify if tremor-suppressing medications are contraindicated due to a coexisting medical condition or drug allergy Stable doses of all medications for 30 days prior to study entry Patients which have not completed the MRgFUS procedure Patients which were diagnosed during the trial with additional diagnoses that can affect motor function, quality of life and symptoms of tremor | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 45.0-80.0, Parkinson Disease At least 45 years of age, and no more than 80 years of age. 2. Meet UK Parkinson's disease brain bank diagnostic 3. Have clinical evidence of rest tremor of one or both upper extremities defined as involuntary, rhythmic oscillations about any joint within the upper extremities 4. Rest tremor amplitude must be at minimum 3 cm as determined by expert opinion by a movement disorders specialist. Confirmation of amplitude measurement will be obtained from the Px1 prior to active participation in the study but will not be used for inclusion/exclusion in study participation. 5. Rest tremor must be historically refractory to at least 2 categories of medications typically used as anti-parkinsonian agents including levodopa formulations, dopamine agonists, amantadine, and anticholinergics. 6. Participants must be able to make no changes to their anti-parkinsonian medications for 150 days (study duration). Ability and safety to do so must also be determined by the participant's treating physician and confirmed in writing prior to participating. 7. Able to provide informed consent History of having undergone botulinum toxin injections for any other condition previously 2. Allergy to carbidopa or levodopa. 3. Prescreening Montreal Cognitive Assessment (MoCA) score less than 22 4. Prescreening muscle weakness as determined by Medical Research Council grade less than 5/5 on direct testing in the upper limb afflicted with rest tremor. 5. Pregnancy: documentation of non-pregnancy by urine pregnancy test will be obtained from all women of child-bearing potential prior to participation 6. Infection at the proposed injection site 7. Those with a pre-existing, concomitant neuromuscular disorder 8. Compromised respiratory function 9. History of having undergone deep brain stimulation surgery for any condition | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 0.0-999.0, Sleep one patient not relevant - one patient not relevant | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Degenerative Arthropathy of Lumbar Spinal Facet Joint The following are for participants Older than 18 years Fluent or native Portuguese language speaker Continuous or intermittent low back pain for at least three months Low back pain with or without irradiation to the gluteal region indicating facet syndrome (pain is aggravated by spine extension or bending toward the affected side; pain is exacerbated by prolonged sitting or walking up steps, as well as retaining one position for a prolonged time) Failure of traditional treatment includes, but is not limited to, physical or drug therapy Understand the purpose of the study Voluntarily provide a free and informed consent form, by themselves or through their partners, and complete the questionnaires, before undergoing infiltration, over the telephone or online during the follow-up The following are for participants Younger than 18 years old Symptomatic lumbar spinal stenosis with claudication or radiculopathy Evidence of radiculopathy Active rheumatologic diseases Congenital or acquired deformities of the lumbar spine Fracture or sequel of lumbar spine fracture of traumatic, pathological or osteoporotic origin Surgical manipulation of the lumbar spine MRI scans of limited quality and incomplete sequences | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 40.0-85.0, Lewy Body Dementia Have dementia as defined by a decline in cognitive function, which in the opinion of the investigator has resulted in functional impairment Meet diagnostic for PD per MDS or DLB per 4th Consensus Report of the DLB Consortium Have a score on the MoCA of 10 Are Modified Hoehn and Yahr Stages 0 Have a blood pressure (BP) or pulse rate at screening and randomization, as determined by three sequential BP/pulse rate measurements in a seated position Participants <60 years old: 1. A mean systolic BP less than or equal to 140 millimeters of mercury (mmHg), a mean diastolic BP less than or equal to 90 mmHg and a mean pulse rate less than or equal 90 beats/minute in a seated position. 2. Each of the 3 systolic BP measurement must be less than 180 mmHg Participants ≥60 years old: 1. A mean systolic BP less than or equal to 150 mmHg, a mean diastolic BP less than or equal to 90 mmHg and a mean pulse rate less than or equal to 90 beats/min in a seated position. 2. Each of the 3 systolic BP measurement must be less than 180 mmHg If on anti-parkinsonian agents, participants must be on stable dosage for at least 3 weeks prior to screening, and should remain on stable doses during the course of the study If on medications affecting cognition (rivastigmine, galantamine, donepezil, memantine), participants must be on stable dosage for at least 3 weeks prior to screening and should remain at a stable dosage during the course of the study If on antidepressant medications, participants must be on stable dosage for at least 3 weeks prior to screening and should remain at a stable dosage during the course of the study Are women of childbearing potential Have significant central nervous system or psychiatric disease, other than PD or DLB, that in the investigator's opinion may affect cognition or the ability to complete the study Have a history in the last 6 months of transient ischemic attacks or ischemic stroke Have a history of intra cerebral hemorrhage due to hypertension Have a history of hypertensive encephalopathy Have atypical or secondary parkinsonism due to drugs (e.g., antipsychotics) or disease (such as progressive supranuclear palsy, essential tremor, multiple system atrophy (e.g. striatonigral degeneration, olivopontocerebellar atrophy), or postencephalitic parkinsonism) Have a current implantable intracranial stimulator or history of intracranial ablation surgery (e.g., subthalamic, globus pallidus-internal segment [GPi]) Have a history of substance abuse within the past 1 year (drug categories defined by the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition [DSM-5], and/or substance dependence within the past 1 year, not including caffeine and nicotine Have a serious or unstable medical illness, other than idiopathic LBD (PDD or DLB), including cardiovascular, hepatic, respiratory, hematologic, endocrinologic, neurologic, or renal disease, or clinically significant laboratory or electrocardiogram (ECG) abnormality as determined by the investigator Have a history in the last 6 months of exertional angina, unstable angina, myocardial infarction, and acute coronary syndrome | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 20.0-59.0, Vitamin D Deficiency Brazilian nationality Living in the UK or in Brazil for more than 2 months Currently receiving treatment for medical conditions that are likely to affect vitamin D metabolism ( osteoporosis therapy, anti-estrogens treatment, antiepileptic drugs, breast-cancer treatment) Hypercalcaemia (>2.5mmol/L) assessed and excluded at baseline Regular use of sun-beds Having a holiday trip for more than 4 weeks, one month prior to commencing the study or plans for a holiday trip out of the country of residence within the study period Use of vitamin supplements containing vitamin D (if the prospective participants agrees to stop Vitamin D supplementation to join the study, a wash-out period of 8 weeks prior to commencing the trial would be acceptable) Pregnant or planning a pregnancy during the study period | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 45.0-85.0, Parkinson Disease Between the ages of 45 and 85 years 2. Diagnosis of PD, Hoehn and Yahr stages I IV, by a fellowship trained neurologist arriving at the diagnosis of PD by applying strict UK brain bank (PD participants only) Neurological disorders other than PD (i.e., stroke, etc.) 2. Difficulty complying due to neuropsychological dysfunction (i.e., severe depression) 3. Allergy to capsaicin or hot peppers 4. History of head or neck cancer 5. History of smoking in the past 5 years 6. Any neurological disorder including PD (Healthy control group only) | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 30.0-999.0, Parkinson Disease (A) participants must be 30 years of age or older. (B) (for the Parkinson groups) diagnosed with PD (ICD-10 code G20) by a physician (neurologist or physician specializing in neurology). (C) They should be able to walk at least 20 steps unassisted (subjects are allowed to get help from assistive devices but not from other persons) (A) The subjects must not be receiving any deep brain stimulation (DBS) treatment while they are participating, but intraduodenal administration of levodopa (Duodopa®) or intradermal administration of apomorphine (Apogo® or Dacepton®) is accepted. (B) .Other extrapyramidal syndromes such as MSA (multiple system atrophy), PSP (progressive supranuclear palsy), CBD (corticobasal degeneration), LBD (Lewy body dementia) or dopamine antagonist drug (such as antipsychotic drug, metoclopramide) induced Parkinsonism will be excluded | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson Disease Over 18 years old Diagnosis of idiopathic Parkinson's disease A score of ≤3 on the Hoehn and Yahr scale Self-reported problem with handwriting (≥1 2.7) Able to communicate in Italian Following a stable medication regimen (no changes in the last 2 weeks and anticipated changes for the course of the study) Severe depression or psychosis (history of) reduced cognition that would preclude active involvement or capacity to consent (according to stages outlined in metal capacity act (ie trigger, information, existing diagnosis, functional test)) Orthopaedic, neurological or other condition that significantly impairs hand function Pregnancy | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 0.0-999.0, Cervical Myelopathy Patients attending either Queen Mary Hospital or Duchess of Kent Children's Hospital, who are over 18 years of age, and present with clinical and radiological signs compatible with cervical myelopathy undergoing laminoplasty. Patients must be literate and able to comprehend the study to be enrolled All patients with previous cervical spine surgery, congenital deformities, spine infection or inflammation, tumour, fusion surgery, non-Chinese, undergoing workman's compensation and unable or refuse to follow the standardized rehabilitation protocol | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-70.0, Dystonia-Parkinsonism, Adult-Onset Parkinson Disease Enrollment in "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688) Diagnosis of Parkinson's disease with and without dystonia Not enrolled in "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688) | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson's Disease Age 18 years or older Able to provide informed consent Clinical diagnosis of Parkinson disease by U.K. Parkinson Society Brain Bank Patients must be stage II -III on the Hoehn and Yahr scale MoCA<25 within the last 6 months Uncontrolled medical condition requiring immediate treatment that would make a walking trial unsafe for the subject Peripheral neuropathy that severely limits gait Current or recent orthopedic disorder that severely limits gait Current uncontrolled depression or major depressive episode Gait disorders other than PD Cannot walk safely without corrective lenses and without support Unable to abstain from PD medications overnight for at least 12 hours before testing History of deep brain stimulation surgery Subjects who are NINDS employees | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson Disease Parkinsonism Diagnosed with PD, or a related condition (e.g. Parkinson's plus, dystonia, tremor) or healthy control participant 2. Age 18 years or over Lack of capacity to consent to participate in the project | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 40.0-80.0, Parkinson's Disease Tremor Men or non-pregnant, non-breastfeeding women 40 to 80 years-of-age who are able to read and understand English Mini Mental State Exam (MMSE) score ≥ 24 Clinical diagnosis of idiopathic Parkinson's disease and presence of at least 2 out of 3 cardinal characteristics (tremor, rigidity, and/or bradykinesia) Hoehn & Yahr Stage I III (inclusive) if not experiencing motor fluctuations. If experiencing motor fluctuations, must be Hoehn & Yahr Stage I IV (inclusive) when OFF or I-III (inclusive) when ON An MDS-UPDRS tremor score (sum of items 2.10, 3.15, 3.16, 3.17, 3.18) of a least 10 (during ON for subjects experiencing fluctuations) (centrally rated) (Forjaz et al., 2015). A limited number of subjects with an MDS-UPDRS of 8 or 9 may be included with Sponsor approval Treated with a stable regimen of anti-parkinsonian and/or anti-tremor medication (with the exception of primidone) for at least 2 weeks prior to screening. Changes to anti-parkinsonian or anti-tremor medications after screening is not permitted Current diagnosis of: a. essential tremor / b. cerebellar disease Presence or known history of: a. significant visual hallucinations (in the opinion of the Investigator and/or Study Safety Representative) / b. significant impulse control disorder (ICD) (in the opinion of the Investigator and/or Study Safety Representative) History or clinical features consistent with an atypical parkinsonian syndrome Dyskinesia or dystonia that would, in the opinion of the investigator, central rater, or Sponsor, interfere with the assessment of tremor Exposure to tremorigenic drugs or drug withdrawal states within the 30 days prior to the first planned dose of study drug Direct or indirect trauma to the nervous system within 3 months preceding the onset of tremor History or clinical evidence of psychogenic tremor origin. Known history of other medical or neurological conditions that may cause or explain subject's tremor Prior MR-guided Focused Ultrasound or surgical intervention (e.g., deep brain stimulation, ablative thalamotomy or gamma knife thalamotomy) for treatment of tremor or Parkinson's disease Use of medication(s) in the past month that might produce tremor or interfere with the evaluation of tremor Inability to refrain from use of medication/substance(s) that might produce tremor or interfere with the evaluation of tremor on study visit days | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 50.0-70.0, Neuro-Degenerative Disease The PD diagnoses were based on the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria. Patients were assessed using the UPDRS III and Hoehn and Yahr disability scale history of head trauma, 2. substance abuse, 3. psychiatric disorder. For healthy controls, additional included 1. any history of neuropsychiatric disorders | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 50.0-99.0, Parkinson Disease Parkinson's disease (PD): PD diagnosis will follow the UK Parkinson's Disease Society Brain Bank Research Center (UKPDSBRC) clinical diagnostic for PD. 2. Hoehn and Yahr stages 2-4 3. Absence of dementia confirmed by cognitive testing. 4. Abnormal 11C-Dihydrotetrabenazine ([11C]-DTBZ) PET study to demonstrate nigrostriatal dopaminergic denervation PD with Dementia (PDD) or dementia with Lewy bodies (DLB). 2. Other disorders which may resemble PD, such as vascular dementia, normal pressure hydrocephalus, multiple system atrophy, corticobasal ganglionic degeneration, or toxic causes of parkinsonism. Prototypical cases have distinctive clinical profiles, like early and severe dysautonomia or appendicular apraxia, which may differentiate them from idiopathic PD. The use of the clinical diagnostic for PD will mitigate the of subjects with atypical parkinsonism. 3. Subjects on benzodiazepine, GABA-ergic medications (baclofen, tizanidine), neuroleptic, anticholinergic (trihexyphenidyl, benztropine), or cholinesterase inhibitor drugs. 4. Evidence of a mass lesion on structural brain imaging (MRI). 5. Participants in whom MRI is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, chest, or cochlear implant. 6. Severe claustrophobia precluding MR or PET imaging. 7. Subjects limited by participation in research procedures involving ionizing radiation. 8. Pregnancy (urine or serum pregnancy test within 48 hours of each PET session) or breastfeeding. 9. History of seizures 10. Significant anxiety or history of panic disorder. 11. History of recent suicide attempt or overdose of tricyclic antidepressants or other medications 12. Any other medical history determined by investigators to preclude safe participation. 13. Allergy to flumazenil 14. Significant liver disease 15. History of alcohol or other substance abuse within past two years. 16. History of regular benzodiazepine use within past year | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 50.0-80.0, Alzheimer Disease For the 3 groups of patients : colonoscopy planned by a gastroenterologist in the context ot the usual medical follow-up of the patient For patients with Alzheimer's disease Patient with early to moderate Alzheimer disease (continuum of patients with mild cognitive impairment due to Alzheimer's disease and patients diagnosed with probable Alzheimer's disease) according to the National Institute of Aging-Alzheimer's Association (NIA AA) Mini-Mental State Examination (MMSE) score ≥18 Has one informant or care partner No parkinsonian syndrome No sign of lewy Body dementia For patients with Parkinson's disease patients with Parkinson Disease according to the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) No dementia sign or cognitive deficit associated to Alzheimer's disease For patients without neurodegenerative disease No history or current neurological/degenerative condition (e.g, lewy body dementia, Parkinson's disease, Parkinsonian syndrome, Alzheimer's disease,…) No memory complaint with a Mac Nair score ≤15 For the 3 groups of patients : History of colonic disorder ((e.g inflammatory condition, adenocarcinoma) contra-indications to colonoscopy For patients with Alzheimer's disease and for patients with Parkinson's disease Any neurological/neurodegenerative condition different from the group to which it belongs (e.g other than Alzheimer's disease for Alzheimer's disease group or other than Parkinson's disease for Parkinson's disease group….) For patients without neurodegenerative disease Any neurological/neurodegenerative condition (e.g lewy body dementia, Parkinsonian syndrome, Parkinson's disease, Alzheimer's disease..) functional colopathy | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-80.0, Parkinson Disease Diagnosis of idiopathic PD according to the UK BRAIN BANK criteria Age between 18 and 80 years Able to walk 25 meters without help or with minimal assistance and sufficient strength to remain standing for at least 20 minutes without assistance for patient report; Stability of drug therapy for Parkinson's disease for at least 4 weeks before the start of the study Mini-Mental State Examination> 25/30 HAM-D (Hamilton Depression Scale) <17 comorbidity with other neurological disorders heart or orthopedic problems Chronic alcohol abuse | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 35.0-80.0, Cerebrovascular Disorders Patients identified as stroke and capable of performing voluntary respiratory maneuvers Increased intracranial pressure Uncontrolled hypertension Complicated arrhythmia Decompensated heart failure Unstable angina Myocardial infarction in the preceding 3 months Pneumothorax, bullae/blebs or infection | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 45.0-999.0, Arterial Hypertension patients enrolled in stage I to III of systemic arterial hypertension signing the free and informed consent term patients who do not agree to participate in the study patients with systolic pressure values greater than 180 mmHg or diastolic pressure above 110 mmHg patients with important comorbidities | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson Disease Diagnosis of idiopathic, typical Parkinson disease according to the UK Brain Bank Criteria; 2. Hoehn & Yahr stages 1-3 (mild to moderate disease severity); 3. Stable on all PD medications for at least 2 weeks prior to study entry; 4. Willing and able to provide informed consent < 18 years of age; 2. Pregnant; 3. diagnosis of atypical Parkinsonism; 4. Hoehn & Yahr stages 4-5 5. a score of > 2 on item 7 of the new freezing of gait questionnaire (moderately or significantly disturbing freezing episodes during daily walking); 6. significant cognitive impairment; 7. unstable medical or concomitant illnesses or psychiatric conditions, which in the opinion of the investigators would preclude successful participation; 8. cardiac problems that interfere with ability to safely exercise 9. orthopedic problems in the lower extremities or spine that may limit walking distance; 10. unable to walk for 10 continuous minutes independently; 11. live in an institution or medical facility (i.e. not in the community) | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 0.0-999.0, Parkinson Disease Patients diagnosed with PD by the United Kingdom Parkinson's Disease Society Brain Bank clinical diagnostic or other standard criteria; PD patients detected with positive LRRK2 variants | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson Disease for Parkinson's patients and "related diseases" controls Parkinsonian patients meeting the Gelb Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease) Woman of childbearing age having an effective means of contraception Informed consent signed by the subject or his legal representative For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative. for of non-ill controls Absence of rest trembling, bradykinesia and stiffness MMSE (Mini Mental State Examination) greater than 25 Woman of childbearing age having an effective means of contraception subject having signed the informed consent for non-inclusion of patients Clinical for of the diseases described Participation in another therapeutic trial or in the period of a previous clinical trial. for non-inclusion of non-ill controls Functional discomfort in daily life of unknown cause MMSE less than 25 Participation in another therapeutic trial or in the period of a previous clinical trial | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 34.0-74.0, Prostate Cancer Localized prostate cancer undergoing radical prostatectomy Patient has to understand and be able to write and read Finnish language No prior head injury, dementia or Parkinson's disease No concomitant malignant illness Life expectancy of at least 10 years 74 years of age Locally advanced prostate cancer (T4) Suspicion or documented metastases (M1) Serum PSA > 20 ng/ml Prior laparoscopic hernia surgery employing non resorbable mesh Prior pelvic irradiation or major surgery Prior malignant disease within prior 5 years excluding skin cancer (non-melanoma) | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 40.0-80.0, Parkinson's Disease Age from 40 to 60 years, and no limitation of gender. 2. Diagnosis of primary Parkinson's disease(PD) according to Movement Disorder Society (MDS)-PD established in 2015. 3. Hoehn-Yahr Stages from I to IV stage. 4. Drugs for anti Parkinson's disease have been taken over 28 days before entering the group. 5. MMSE score≥25 6. No antidepressant or antipsychotic drugs were received within 2 weeks. 7. Understanding and willingness to sign a written informed consent document Patients with PD have to be disqualified from this study if any of the following is applicable. 1. Patients with psychiatric history, but depression. 2. Suicidal tendency or behavior of patients. 3. Patients with severe cognitive impairment, chronic organ failure or malignant tumor. 4. The value of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) was 1.5 times higher than that of the normal reference; or leucocyte count<1000/μl. 5. Pregnancy and lactating women. 6. The patient is taking part in other drug tests, or received other research medication within 90 days before entering the group. 7. Patients who had quit our study could not enter it again | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 25.0-90.0, Parkinson Disease, Essential Tremors and Dystonia Dopa responsiveness 2. Minimum disease duration of 5 years. 3. Diagnosis of idiopathic Parkinsons disease 4. Patients with intractable Essential Tremors. 5. Patients with intractable dystonia Significant medical health problems. 2. Significant cognitive impairment 3. Bleeding tendencies | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 65.0-80.0, Parkinson Disease diagnosis of Parkinson's disease according to the United Kingdom Brain Bank criteria in stage 2-3 of the disease evolution according to the Hoehn and Yahr treated with levodopa or its synergists capable to walk independently indoors without aid referring 5 years of education or more presence of other neurological (excluding PD), orthopedic or cardiopulmonary problems visual and auditory deficiency uncorrected dementia [assessed by Montreal Cognitive Assessment (MoCA), cut-off 26] depression [according to the Geriatric Depression Scale (GDS-15), cut-off 6] declined imagery capacity [according to the Revised Movement Imagery Questionnaire (MIQ-R) cut-off 10] | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, HIV HIV+ and on ART Has moderate or severe household food insecurity Has detectable viral load (>50 copies) and/or suboptimal adherence to ART Does not meet above | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson Disease Have a clinical diagnosis of idiopathic PD according to the MDS clinical diagnostic for Parkinson's disease. 2. Positive [¹²³I]FP-CIT single photon emission CT (DaTscan) confirming nigrostriatal degeneration 3. Diagnosed within one year from enrolment 4. Hoehn and Yahr score <= 2 at enrolment 5. Optimal symptomatic therapy, not requiring adjustments, for at least 3 months Dementia or other neurological disorder at baseline visit 2. Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit 3. Prior use of dopaminergic treatment | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 30.0-999.0, Parkinson Disease Parkinson's disease Stable on levodopa therapy with fluctuations Chronic gastrointestinal disease Recent antibiotic or probiotic therapy Pregnant Immunocompromised | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 50.0-999.0, Parkinson Disease Males and females over age 50 Meet for typical idiopathic PD Hoehn & Yahr stage I-III Treated with levodopa/carbidopa Have PD with Mild Cognitive Impairment (PD-MCI) according to Movement Disorders Society (MDS) Level II diagnostic criteria Medications should be stable for 4 weeks prior with no changes planned during the study (we will document any unplanned changes) Dementia according to MDS or MoCA score <21 Other neurological disorders Brain surgery History of psychotic disorder Change in medication during the study Treatment with medications that interfere with cognition (e.g. anticholinergics) Any condition that would interfere with participation (e.g., non-English speaking, significant current depression) | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Cirrhosis Hepatic Encephalopathy Minimal Hepatic Encephalopathy Covert Hepatic Encephalopathy Age >18 years 2. Cirrhosis defined by any one of the following 1. Cirrhosis on liver biopsy or transient wave elastography 2. Nodular liver on imaging 3. Endoscopic or radiological evidence of varices in a patient with chronic liver disease 4. Platelet count <150,000/mm3 and AST/ALT ratio >1 in a patient with chronic liver disease 5. Patients with frank decompensation (ascites, HE, variceal bleeding, hepato-pulmonary syndrome) 3. Prior HE controlled on standard of care therapy defined as lactulose or rifaximin for at least 2 months prior to enrollment. 4. Serum albumin <4 gm/dl 5. Cognitive impairment on any of the three testing strategies for HE including Psychometric hepatic encephalopathy score (PHES), Stroop test and Critical Flicker Frequency 1. PHES aggregate score <-4SD based on norms published in Allampati et al located at the website www.encephalapp.com 2. Stroop OffTime+OnTime values greater than norms published in Allampati et al located at the website www.encephalapp.com 3. Critical Flicker Frequency value <39 Hz Unclear diagnosis of cirrhosis (does not meet the outlined above) 2. No prior overt HEepisodes 3. HE uncontrolled on standard of care defined as a mini-mental status exam<25 4. On regular IV albumin infusions due to scheduled paracentesis within the last 3 months 5. Recent alcohol abuse (within 3 months) 6. Unable to give consent 7. Current or recent invasive bacterial or fungal infections (<1 month) 8. Allergic reactions to IV albumin 9. Current or recent congestive heart failure (Systolic ejection fraction <25%) within the last year 10. Pregnancy (positive urine pregnancy test at screening) 11. In the opinion of the PI, those who are unlikely to survive 6 weeks or be able to adhere to the trial activities | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 40.0-999.0, Parkinson Disease at least 40 years of age neurologist-diagnosed Parkinson's Disease Hoehn & Yahr (H&Y) stages 1 to 4 were able to walk 10 m with or without aids visual, auditory, and orientational problems affecting study results orthopedic problems affecting walking other neurologic conditions, cardiovascular, musculuskeletal, and vestibular disease | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 40.0-80.0, Parkinson Disease Diagnosis of idiopathic Parkinson's and Hoehn and Yahr score of 2.5 or more; Willing to participate and refrain from driving whist taking zolpidem/placebo; Within age range 40 to 80 years Any contraindications as stated in Summary of Product Characteristics (SmPC) for zolpidem:- Hypersensitivity to zolpidem tartrate; Obstructive sleep apnoea; Myasthenia gravis; Severe hepatic insufficiency; Acute and/or severe respiratory depression; Psychotic illness. and in addition Unable or unwilling to give informed consent ; Current therapy with central nervous system (CNS) depressants; Current therapy with Cytochrome P450 (CPY450) inhibitors or inducers (specifically CYP3A4); Pregnancy and breast feeding women; History of alcohol or substance abuse; Employed in a role that involves driving or operating heavy machinery; Participation in another interventional clinical trial | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 60.0-75.0, Parkinson Disease Able to provide informed consent. 2. A clinical diagnosis of idiopathic PD. 3. A stable and optimal medical regimen of anti-parkinsonian drug therapy for the duration of the study. 4. Modified Hoehn and Yahr stage between 1.0 and 3.0 in the OFF state. 5. Right-hand dominant and primarily right-side affected to prevent confounds due to handedness and affected side An uncontrolled medical condition (i.e. hypertension, diabetes, etc). 2. Evidence of secondary or atypical parkinsonism as suggested by: 1. History of CVA's, exposure to toxins, neuroleptics or encephalitis. 2. Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze palsy or significant orthostatic hypertension. 3. Metal in the skull or the eye, such as a cardiac pacemaker, brain stimulator, shrapnel, surgical metal, clips in the brain, cochlear implants, and metal fragments in the eye, as these may make TMS and tDCS unsafe. 4. An uncertainty about the presence of metal objects in a subject's body exists. 5. Hearing loss, have had a brain tumor, a stroke, head trauma, epilepsy or a history of seizures, have another neurological disorder other than a movement disorder, or have a head injury where they passed out for more than a few seconds. 6. Pregnant or thought to be pregnant. 7. Irrepressible dyskinesia or tremor to prevent the confound of excessive EMG during TMS testing at rest. 8. Any other neurological disorders. 9. Meeting of any of the TMS given in international guidelines | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-65.0, Multiple Sclerosis diagnosed with MS based on McDonald any neurological condition other than MS | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-80.0, Parkinson Disease The primary for diagnosis are idiopathic Parkinson's disease, defined as bradykinesia with resting tremor or muscular rigidity according to MDS-PD diagnosis (2015). The examination of major symptoms needs to be performed by the methods described in the Unified Parkinson's Disease Rating Scale (UPDRS) Definite cerebellar abnormalities, such as cerebellar gait, limb ataxia, or cerebellar eye movement abnormalities (such as sustained staring induced nystagmus, giant square wave beats, and distant hypertonia) Downward vertical suprachiasmatic gaze palsy, or selective downward vertical scanning is slowing down Within five years of onset, the disease was diagnosed as a likely frontotemporal dementia or primary progressive aphasia (according to revised diagnostic for frontotemporal dementia published in 2011) With more than three years after the onset of the disease, Parkinson's disease symptoms are still limited to the lower limbs They have been treated with dopamine receptor blockers or dopamine depletion agents and the dosage and duration of administration are consistent with the diagnosis of drug-induced Parkinson's disease Although the condition is at least moderately severe, there is no discernible effect on high-dose levodopa therapy Definite cortical hypoesthesia (such as loss of skin writing and body recognition when the primary sensory function pattern is complete), definite motor aphasia of body concept, or progressive aphasia Functional neuroimaging study of the presynaptic dopaminergic system shows normal results There is evidence of Parkinson's disease or other diseases suspected to be related to the patient's symptoms, or professional physicians identify they may be other syndromes rather than Parkinson's disease based on a complete diagnostic assessment | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 50.0-999.0, Early Parkinson Disease Key 1. Diagnosed with "Clinically Probable PD" according to the MDS clinical diagnostic with documented onset of symptoms per treating physician's records within three years of the Screening visit. Disease severity according to modified Hoehn & Yahr stage ≤ 2; 2. Projected to not require to start dopaminergic therapy within 9 months from Baseline; 3. Female subjects must be not of childbearing potential, e.g., documented evidence that they are surgically sterile (e.g., hysterectomy, partial hysterectomy, bilateral oophorectomy, bilateral tubal ligation), or post-menopausal (at least 12 months since last menses) prior to Screening with serum Follicular Stimulating Hormone (FSH) ≥40 mIU/mL). Key Current, or within 60 days of Screening, use of any prescription, investigational, or over the counter medication for the symptomatic treatment of PD or to slow the progression of PD. Treatment with Monoamine Oxidase B (MAOB) inhibitors will be allowed if the dose is stable for at least 30 days prior to Screening and subjects agree to remain on it for the duration of the study; 2. Prior use of dopaminergic therapy (e.g., levodopa, dopamine agonist, amantadine) for 30 or more days any time in the past; 3. A diagnosis of a significant central or nervous system disease affecting the subject's cognition or motor function at any time, such as another neurodegenerative disorder, multiple sclerosis or stroke. This does not transient neurological deficits such as transient ischemic attacks or migraine aura; 4. A diagnosis of a medical condition that could interfere with interpretation of the MDS-UPDRS during the trial (e.g., musculoskeletal disorders); 5. Most recent DaT SPECT scan not compatible with PD (i.e., Scans Without Evidence of Dopaminergic Deficit [SWEDD]) based on central read by a study physician; 6. MRI scan of the brain performed after onset of PD suggestive of secondary Parkinsonism (e.g., subdural hematoma, normal pressure hydrocephalus, or infarcts of the basal ganglia); 7. Any clinically significant cardiac abnormality in the opinion of the investigator. This would myocardial infarction in the six months prior to screening, or significant ECG abnormality, including heart-rate corrected interval QT (QTc) based on Fridericia's correction formula > 470 milliseconds; 8. Subject report of recent (6-month) illicit drug use (other than marijuana), or excessive intake of alcohol (as per investigator opinion); 9. Subject report of marijuana use within one month of Screening or subject not willing to forgo marijuana use through the trial; 10. Participation in other investigational drug trials within 30 days prior to Screening; 11. Any concomitant medication or medication excluded that could put subject at risk, or interfere with study evaluations (Section 7.4); 12. Recent use of medications that can cause Parkinsonism and suspicion of the investigator that it could have worsened the subject's Parkinsonism. This includes neuroleptics (e.g., olanzapine, risperidone, haloperidol), some anti-nausea medications (e.g., prochlorperizine, metoclopramide) and others (e.g., flunarizine, methyldopa); 13. Use of medications that affect the dopamine system though do not cause or treat PD, within 60 days of Screening. This includes stimulants (e.g., methylphenidate, amphetamine derivatives, modafinil) and Monoamine Oxidase A (MAOA) inhibitors (e.g., phenelzine, and tranylcypromine). Note that antidepressants are acceptable as long as the subject has remained on them at a stable dose for over 60 days prior to Screening and plans to remain on them through the study; 14. Any malignant disease other than basal cell carcinoma of the skin with evidence of disease within the past 5 years, or with the potential for recurrence | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 21.0-99.0, Parkinson Disease Individuals with a diagnosis of Parkinson's Disease (made by movement disorders specialist) will be included in this study. Additional self-reported ability to walk ~6 minutes overground as well as walk on a treadmill for a total of 10 minutes with rest breaks as needed, and be classified as Stage 2, or 3 on the Hoehn and Yahr Scale (Goetz et. al, 2004) Hoehn and Yahr Stages 1, 4, or 5, uncontrolled cardiorespiratory/metabolic disease (e.g., cardiac arrhythmia, uncontrolled hypertension or diabetes, orthostatic hypertension, chronic emphysema), or other neurological or orthopedic disorders that may affect walking. The investigators will also participants with severe communication impairments, which could impede understanding of the purpose or procedures of the study or an inability to comply with experimental procedures | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 0.0-999.0, Functional Movement Disorder Patients with a clinical diagnosis of Functional Movement Disorder (e.g. functional tremor, functional dystonia, functional myoclonus) based on Fahn-Williams or OrgMD (e.g. Parkinson disease, essential tremor, cervical dystonia) evaluated by a fellowship-trained movement disorder neurologist at Cleveland Clinic 2. Patients with mild to severe involuntary movement as a result of the movement disorder, visible for video-recording Significant cognitive impairment that prevents proper informed consent 2. Patients whose movement disorders cannot be captured on video | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 0.0-999.0, Parkinson Disease Essential Tremor Dystonia Must be previously treated with or eligible for implantation with a deep brain stimulation system | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 0.0-999.0, Parkinson Disease Diagnosis of classic PD with history of clinically meaningful response to levodopa Disease duration >15 years since diagnosis Hoehn & Yahr stage >IV "on" or "off" levodopa Consent signed by subject, if possible If subject is cognitively impaired, consent signed by power of attorney or legally authorized subject representative Assent from the study subject, if possible Stable dose of all medications for 60 days prior to Day 1 of first week of study Atypical parkinsonian syndrome (e.g., never responded to levodopa, and/or atypical signs) Acute or unstable medical condition such as heart disease, kidney and liver failure History of HIV, hepatitis B and C Use of moderate to strong CYP 3A4 modulators (see both inhibitors and inducers in Appendix BB) | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 40.0-70.0, Idiopathic Parkinson's Disease Right-handedness (as assessed by the Edinburgh Handedness Inventory) 2. Being in stable treatment with the administration of L-dopa and dopamine agonists (i.e. not having motor fluctuations and/or dyskinesia) 3. Having a Hoehn & Yahr score between 1.5 and 3 Presence of severe sensory deficits 2. Presence of overt signs of dementia (a. mini-mental state examination, MMSE must be ≥24; b. intelligence quotient ≥75). 3. Comorbidity with other psychiatric disorders that might interfere with task execution (i.e. attentional disorders). 4. Presence of severe tremor or rigidity of the right arm in the OFF medication state | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Vascular Diseases Carotid Artery Diseases Aneurysmal Disease Peripheral Artery Disease All patients attending for aortic aneurysm repair, carotid artery surgery and lower limb revascularisation under the care of the Vascular Surgery team 2. Willing and able to give informed written consent Those unable to give informed written consent 2. Those <18 years of age 3. In the opinion of the investigator unable or unwilling to comply with the requirements of the study | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-90.0, Neck Pain Cervical Pain years old and over Medical diagnosis of chronic cervical pain (more than 3 months of cervical pain evolution) Positive flexion rotation test Recent spine, head or mouth surgery Diabetes mellitus Recent infection and/or inflammatory arthritis, and cervical and/or brain traumatism records Contraindication for manual therapy or cervical training | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 6.0-12.0, Closed Loop Diabetes Mellitus, Type 1 Young Children (6 to 12 Years Old ) Prepubescent children (Gender: both) aged between 6 to 12 years old (Tanner stage 1) at time of screening Type 1 diabetes as defined by WHO for at least 1 year or confirmed C peptide negative An insulin pump user for at least 3 months Subject having a Glycosylated hemoglobin (HbA1c) blood value < 9% at time of screening visit-based on analysis from local laboratory within 3 months Subject having a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units Subject and his parent/guardian willing to spend 3-overnight in hospital Subject willing to wear the system continuously throughout the study Subjects and his parent/guardian must be able to speak and be literate in French or Flemish as verified by the investigator Children who are in pubertal stage Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization) Coma Seizures Subject having sever DKA in the 6 months prior to screening visit Known or suspected allergy against insulin Any other physical or psychological disease, or medication likely to interfere with the conduct of the study and interpretation of the study results as judged by the investigator Subject is unable to tolerate tape adhesive around the sensor or pump placements Subject has a cardiovascular condition which the investigator determines should the subject, i.e. ventricular rhythm disturbance, hypertrophic cardiomyopathy | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Reconstructive Surgery After Carcinological Excision Patient eligible for reconstructive surgery after carcinological excision following a decision taken in a multidisciplinary consultation, and for whom the envisaged oral defect concerns either the soft tissues of the oral cavity and oropharynx, or the mandibular bone Scheduled post-operative radiotherapy Coverage by the Social Security system Capacity to provide informed consent Post-traumatic substance loss (ballistic autolysis) Surgical or anesthetic contraindication (physiological age, other proposed therapeutic options) Pregnant or breastfeeding woman Subject incapable of full age or deprived of liberty Indication for chemotherapy with highly neurotoxic agents Inability to complete questionnaires or express feelings during the examination Any situation judged by the investigator as a contraindication to neurorrhaphy | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 50.0-80.0, Osteo Arthritis Knee Knee Arthroplasty patients scheduled for unilateral TKA secondary to osteoarthritis age from 50 to 80 years old participants were not engaged in preoperative treatments participants who were undergoing a revision TKA body mass index (BMI) greater than 40 kg/m2 participants who were receiving a bilateral TKA's uncontrolled hypertension diabetes mellitus a history of any neurological disorder multiple sclerosis Parkinson's disease patients with rheumatoid arthritis or active cancer previous history of deep vein thrombosis | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 7.0-7.0, Typical Development Risk of Dysgraphia Dysgraphia Children in the second grade (aged 7 years old) Participation agreement Diagnosed or suspected of neurological disabilities (e.g., cerebral palsy, epilepsy), psychiatric and/or behavioural disorders Presence of uncorrected vision and hearing problems Referenced by Special Education/National Service of Early Intervention in Childhood Presence of one or more school retentions Native language is not Portuguese Children with direct intervention in graphomotor skills or who had a similar intervention to that proposed less than 1 year ago Participation in the intervention program of less than 80% Children undergoing drug therapy (e.g., antihistamines) that interfere with the study variables Do not wish to participate in the study | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 20.0-80.0, Parkinson's Disease Subject fulfills the UK Parkinson's Disease Society brain bank clinical diagnostic criteria Parkinson's disease patients in Stages 2 to 4 on the Modified Hoehn and Yahr Scale. (mH&Y, Evaluation at ON state for patients who experience Wearing-off phenomenon) MDS-UPDRS partIII score of >= 15. (Evaluation at ON state) Subject who are responsive to levodopa/DCI (carbidopa or benserazide) combination therapy and who have been on the therapy for 6 months or longer without interruption at enrollment Subject who have not started any new antiparkinsonian drugs and have been on a stable regimen of antiparkinsonian drugs in the 3 months before enrollment Use of any CYP3A4/5-related drugs within 2 weeks prior to enrollment Use of any of the following drugs within 3 months (or 6 month in case of depot preparations) prior to enrollment; Antipsychotics, tiapride, metoclopramide, amoxapine, reserpine, tetrabenazine, methyldopa, papaverine, Levodopa/carbidopa intestinal gel and apomorphine hydrochloride injection Treatment by transcranial magnetic stimulation (TMS) within 6 months prior to enrollment Neurosurgical operation for Parkinson's disease. (stereotactic surgery, deep brain stimulation or gamma knife) Subject who have received administration of adenosine A2A receptor antagonist Either of the following consecutively at screening and enrollment; Resting Pulse > 100 bpm Resting systolic blood pressure > 140 mmHg, or diastolic blood pressure > 90 mmHg Significant dementia or a Mini-Mental State Examination (MMSE) score of =< 23 Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating Scale (C-SSRS) at baseline Anyone otherwise considered unsuitable for the study by the investigator or subinvestigator including those who are unable to communicate or to cooperate with the investigator or subinvestigator | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 40.0-80.0, Parkinson Disease Movement Disorders Men and women between the ages of 40 and 80 years Diagnosis of idiopathic Parkinson's disease based on the UK PD Brain Bank criteria35 PD diagnosis within 5 years (≤ 5 years) Hoehn and Yahr severity stage less than or equal to 3 (Mild to moderate bilateral disease; some postural instability; physically independent).36 Remain untreated with levodopa or a dopamine agonist for the duration of the study (up to 7 months, can have treatment with MAO-B inhibitors rasagiline or selegiline) Able to understand and give informed consent for the study Able to stand and walk unassisted Current use of dopamine-blocking therapy or significant history of dopamine-blocking therapy (> 1 yr of daily use of the following: typical and atypical antipsychotics except for quetiapine and clozapine, metoclopramide, prochlorperazine, tetrabenazine, reserpine) Autoimmune disease or current anti-inflammatory or immunomodulatory therapy (aspirin, Tylenol, ibuprofen, naproxen OK) Other condition already causing gait dysfunction or likely to cause significant change in motor/gait function over 6 month period (i.e. knee or hip replacement within the past 6 months or surgery planned during the study, peripheral neuropathy causing impaired proprioception at big toes) History of treatment with carbidopa/levodopa, dopamine agonist, or amantadine (can have history of treatment with MAO-B inhibitors rasagiline or selegiline) Patient anticipates that they will require symptomatic treatment for PD within the next 6 months | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-70.0, Cirrhosis for EHM+ subjects Age between 18 and 70 (inclusive) Cirrhosis Minimal hepatic encephalopathy Expression of non opposition for EHM subjects Age between 18 and 70 (inclusive) Cirrhosis No hepatic encephalopathy (minimal or clinical) Paired with EHM+ subjects about age, gender, MELD score and cirrhosis etiology for all subjects Age older than 70 MMS score < 24 Clinical hepatic encephalopathy Cirrhosis etiology different from alcoholic, viral or metabolic one Intake of psychotropic drugs within 48h Alcohol intake > 30 g/j Heart, renal or respiratory failure Evolutive neurological diseases History of neurological diseases causing consequences | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson Disease Patients aged ≥ 18 years Patients affected by Parkinson's disease (PD) according to the diagnostic of the United Kingdom Brain Bank, in the ON phase of their usual treatment Hoehn-Yahr Stage from 1 to 3 Signature of the Informed Consent and of the privacy form Patients with symptoms and signs compatible with atypical parkinsonism PD patients treated with antagonist drugs for central dopaminergic receptors (first and second generation antipsychotics) in the last 6 months before enrollment Patients suffering from other neurological diseases Patients with evident cognitive impairment (MMSE <24/30) Patients with manifest eye movement disorders prior to the diagnosis of PD Patients with daltonism Patients with amblyopia Patients suffering from high anisometropia Patients suffering from advanced cataracts Patients suffering from glaucoma | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-75.0, Hypertension Cardiovascular Diseases Vascular Diseases BP>=140/90 and <=180/110 mm Hg at time of discharge from ED Verbal fluency in English or Spanish Age 18-75 years Unable to verbalize comprehension of study, impaired decision-making or documented dementia Plans to move from Chicago area within the next year Pregnant or trying to get pregnant | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-80.0, Liver Failure as A Complication of Care Patients subjected for major liver surgery (4 or more Couinaud segments) or patients undergoing a 2nd, 3rd or 4th hepatic resection. Pre-operative chemotherapy and/or biological agents are allowed Primary PHLF occurring early after surgery defined by the 50:50 (from PO day 5 to day 14) or by the presence of hepatic encephalopathy grade 2 or more and the 50:50 (from PO day 3 to 4) Written informed consent ALPPS (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy) procedure In patients with chronic liver disease presence of significant portal hypertension (hepatic venous pressure gradient ≥ 10 mmHg and/or Fibroscan ≥ 21kPa) prior to surgical intervention Any contraindication for MARS therapy such as uncontrolled active bleeding, platelet counts <20.000 /µl or uncontrolled infection (presence of fever or adequate antibiotic therapy for less than 48h), septic shock, haemodynamic instability requiring inotropic support (noradrenaline > 1mg/h) PHLF occurring after post operative day 14 Secondary PHLF: post-operative liver failure secondary to vascular (outflow or inflow thrombosis) or septic problems Persistant biliary complications (infected biloma, main biliary tree damage) Inability or unwilling of the patient or family to give informed consent | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 8.0-75.0, Dietary Habits Health Behavior Eating Behavior Children ages 8-12 Adults ages 21-75 Elementary schools in Tsaile and Shiprock will have been in existence for at least three years, school size (have between 40 to 100 students in grades 3 and 4 combined), have more than two-thirds Navajo students and satisfy a garden site checklist that can overcome garden barriers (e.9. have access to water) Assessment is restricted to Male/female students in grades 3 and 4 attending, attending school in either Tsaile or Shiprock and one family member (Navajo adult aged 18 and older) for each child Family member child dyads neither of which are Navajo Family member/child dyads not expected to stay at the recruited Tsaile or Shiprock elementary school for the whole school year | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson Disease Patients having Parkinson's disease according to United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) All Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and in need of the establishment of a second line treatment by subcutaneous apomorphine infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical care of their Parkinson's disease Patient able to give its free and informed consent Patient having a social security Patients presenting atypical Parkinson's syndrome Patients having a deep brain stimulation Patient having a psychiatric disease such as: mood disorders, psychotic disorder… Patients presenting a cognitive decline evaluated by a Montreal Cognitive Assessment (MoCA) score inferior to 24 None ability to give its consent Patients unable to realize the tests provided in the context of this study Patients under supervision, curators, or legal guardian Patients non-affiliated to a social security Patients in period of another study | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-80.0, Essential Tremor Parkinson's Disease Parkinson's disease patients: 1. Patient must provide written informed consent prior to any clinical study related procedure. 2. Patient is 18 to 80 years of age. 3. Patient is diagnosed with Parkinson's disease for at least 4 years according to standard practice. 4. Patient is willing to maintain a constant dose of anti-Parkinson's disease medication indicated as best medical management for at least 1 month prior to study enrollment. 5. Patient is willing and able to comply with the follow-up schedule for the length of the study. 6. Patient has been implanted with an 8-channel directional Infinity deep brain stimulation system in the subthalamic nucleus (STN) within the last 12 months. 7. Patient has had stable deep brain stimulation programming settings for at least 1 month prior to study enrollment. Essential tremor patients: 1. Patient must provide written informed consent prior to any clinical study related procedure. 2. Patient is 18 to 80 years of age. 3. Patient is diagnosed with essential tremor for at least 4 years according to standard practice. 4. Patient is willing to maintain a constant dose of anti-tremor medication indicated as best medical management for at least 1 month prior to study enrollment. 5. Patient is willing and able to comply with the follow-up schedule for the length of the study. 6. Patient has been implanted with an 8-channel directional Infinity deep brain stimulation system in the ventral intermediate (Vim) thalamus within the last 12 months. 7. Patient has had stable deep brain stimulation programming settings for at least 1 month prior to study enrollment Individuals unable to make the decision to participate in a clinical investigation on their own. 2. Patient is currently programmed with segmented electrodes, and cannot tolerate omnidirectional programming. 3. Patient is being evaluated for a lead revision. 4. Patient has untreated clinically significant depression. 5. Patient has dementia that interferes with their ability to co-operate or comply with study requirements or comprehend the informed consent, as determined by the investigator. 6. Patient abuses drugs or alcohol. 7. Patient is currently enrolled or plans to enroll in another concurrent study that may confound the results of this clinical investigation. 8. Patient has a confirmation of diagnosis of a terminal illness associated with survival <12 months. 9. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the patient's ability to participate in the clinical study or to comply with follow-up requirements, or impact the scientific soundness of the clinical study results. 10. Pregnant or nursing patients and those who plan pregnancy during the clinical study follow-up period | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-85.0, Parkinson Disease Clinical diagnosis of Parkinson's disease according to the UK Brain Bank criteria Subjects had clinically moderate to advanced severity of disease (Hoehn and Yahr stage 2 Subjects whose medical treatment had been on stable dosage of dopaminomimetics for at least 4 weeks before the study Subjects ability to walk with or without assistive device Subjects had cardiovascular, inflammatory or musculoskeletal problems that could prevent them to participate in an exercise program Subjects whose mini mental status examination score was less than 26 | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 40.0-999.0, Parkinson's Disease Men or women aged 40 and older with the diagnosis of idiopathic PD per UK Brain Bank Hoehn-Yahr Stage I-III, on stable dopaminergic treatment regimen for equal or greater than 4 weeks prior to baseline Aerobic Fitness: VO2max below "very good" fitness levels for their age and gender at baseline cyle ergometry. To subjects who have room to improve their aerobic fitness, the investigators will enroll only those subjects whose VO2max is below "very good" fitness level (about 90% of the population) using age and gender based VO2max norms based review of 62 studies where VO2max was measured directly in healthy adult subjects in the USA, Canada and 7 European countries (Reference: Shvartz, E and Reibold, RC. Aerobic fitness norms for males and females aged 6 to 75 years: a review. Aviat Space Environ Med. 1990; 61:3-11) Cognitive function: No dementia per Movement Disorder Society Level I (Reference: Dubois, B, Burn, D, Goetz, C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007; 22:2314-2324) Current active drivers with a valid driver's license Veteran or non-veteran Subjects unwilling or unable to give informed consent Secondary parkinsonism (e.g., drug induced) Parkinson-plus syndromes History of brain surgery for PD such as deep brain stimulation Corrected visual acuity less than 20/50 (due to effect on driving) Contraindications to exercise per ACSM for Exercise Testing and Training (Reference: American College of Sports Medicine. Cardiorespiratory Exercise Prescription. In: Ehrman JK, ed. ACSM's Guidelines for Exercise Testing and Prescription.6th ed. Baltimore: Lippincott Williams & Wilkins, 2010:448-462) No confounding acute or unstable medical, psychiatric, orthopedic condition. Subjects who have hypertension, diabetes mellitus, depression, or other common age related illness will be included if their disease under control with stable treatment regimen for at least 30 days Clinically significant TBI or PTSD Presence of other known medical or psychiatric comorbidity that in the investigator's opinion would compromise participation in the study Presence of dementia per Movement Disorder Society Level I | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-75.0, Portal Hypertension Hepatic Encephalopathy The patient's gender is not limited, ≥ 18 years old and ≤ 75 years old; 2. Clinically diagnosed post-hepatitis B cirrhosis; 3. History of esophageal varices venous rupture confirmed by endoscopy, re-bleeding after standard treatment; 4. Liver function Child A or B; 5. Imaging (CT or MRI) suggests that the left/right first branch of the intrahepatic portal can construct a shunt; 6. Platelet count ≥ 50 × 109 / L; 7. Prothrombin time (PT) does not exceed the upper limit of the normal control for 3 seconds; 8. Serum creatinine concentration ≤115umol/L; 9. Patients and their families agree to join the clinical trial and sign an informed consent form Imaging confirms portal vein thrombosis; 2. Patients who have undergone previous surgical treatment of portal hypertension (including splenectomy, surgical disconnection or shunt); 3. Combine any malignant tumor; 4. History of previous hepatic encephalopathy; 5. Consolidation of intractable ascites; 6. Pulmonary artery pressure > 40 mmHg, left ventricular ejection fraction < 50%, congestive heart failure or severe valvular insufficiency; 7. Others: persistent active bleeding, vital signs can not be maintained, blood ammonia ≥ 100, total bilirubin > 51umol / L failed to improve after symptomatic treatment; combined active infection, especially biliary system inflammation; female patients are pregnant Or lactation; severe contrast allergy | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Prostate Adenocarcinoma Each patient must meet all of the following to be enrolled in the study Age >/= 18 years and are capable of giving informed consent. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care Patients must have a pathologically confirmed diagnosis of prostate adenocarcinoma. Features of neuroendocrine phenotype are allowed Patients must have evidence of castration resistant metastatic disease and eligible for Enzalutamide per standard guidelines. Castration resistant non-metastatic disease is allowed in phase I study if subject is candidate for Enzalutamide Patients must have and ECOG performance status of ≤ 2.(appendix D) Patients must be on continuous LHRH agonist or antagonist treatment or surgically castrated with castrate levels of testosterone (< 20 ng/dl) Any number of prior chemotherapy regimens are allowed. Chemotherapy naïve patients are allowed If patient is already on Enzalutamide at a dose of 160mg daily, he is allowed if he can have baseline image and PSA within 1 month of the start of entinostat Patients may have had androgen synthesis inhibitors or other investigational drugs. Patient must have discontinued flutamide or nilutamide or other AR targeted agents (including abiraterone) for at least 4 weeks and bicalutamide for at least 6 weeks prior to day 1 of treatment Patients receiving treatment with bisphosphonates or denosumab must remain on treatment during the study Patients meeting any of the following are not to be enrolled in the study Patient was treated and discontinued Enzalutamide previously for any reason Major surgery within 28 days or serious infection requiring IV antibiotics within 14 days preceding the first dose of study treatment Patient has received other investigational drugs within 14 days before enrollment Known GI disease or GI procedure that could impact drug absorption in the upper bowel, or tolerance of Entinostat. Examples but are not limited to partial gastrectomy, small bowel resection, pancreatectomy, malabsorption or celiac disease Ongoing nausea or vomiting of any severity without improvement after appropriate treatment > Grade 1 diarrhea, not controlled with appropriate treatment History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease requiring supplemental oxygen Clinical and/or radiographic evidence of cerebral metastases. However, patients who have a history of central nervous system (CNS) metastasis but who have no radiographic or clinical evidence of residual tumor (eg, following complete surgical resection or stereotactic radiosurgery) are not excluded from participation in this study | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson Disease A diagnosis of idiopathic PD Sufficient knowledge of the Dutch language to fill out questionnaires Age 18 years or older at the time of diagnosis All disease stages, regardless of disease severity or disease duration Not having received care from a PDNS in the past two years A score of ≥ 18 on the Mini-Mental State Examination (MMSE13) and ≥ 12 on the Frontal Assessment Battery (FAB14) A type of atypical parkinsonism caused by medication (e.g. neuroleptics), a metabolic disorder (e.g. Wilson's disease), encephalitis or a neurodegenerative disorder (e.g. multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome) Residing in a nursing home or another type of residential care facility (because the PDNS is not operational there) Any other medical or psychiatric disorder that, in the opinion of the researcher, may compromise participation in the study | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-75.0, Parkinson's Disease • Diagnosis of Parkinson's disease: PD is a clinical diagnosis as defined by the Queen Square Brain Bank (bradykinesia defined as slowness of initiation of voluntary movement with progressive reduction in speed and amplitude on repetitive actions and at least one of the following: Rigidity, 4-6 Hz rest tremor). The diagnosis will have been made by the treating clinician and confirmed by the PI on site after review of the clinical history, examination findings and response to PD medication. The Queen Square brain bank MAY be used to help assist in the diagnosis although this need not be a formal and the relevance of a positive family history of PD, or a confirmed genetic basis for an individual's symptoms will be evaluated in the context of other clinical features in determining diagnosis and eligibility Diagnosis of Parkinson's disease ≤ 3 years ago by a clinician with particular expertise in the diagnosis and treatment of movement disorders (typically one of the PIs or their consultant colleagues). The date of diagnosis will be verified by a review of the medical records Subjective improvement of motor impairment on dopaminergic medication, confirmed by PI through personal examination and/or review of medical records Hoehn and Yahr stage ≤ 2.5 in the practically defined "ON" medication state. This implies that all patients will be mobile without assistance during their best "ON" medication periods Ability to take study drug Ability to communicate in English Age 18 yr of any gender Documented informed consent to participate Able to comply with study protocol and willing to attend necessary study visits Diagnosis or suspicion of other cause of parkinsonism such as Multiple system atrophy (MSA) or progressive supranuclear palsy (PSP), drug induced parkinsonism, dystonic tremor or essential tremor will not be recruited Known abnormality on CT or MRI brain imaging considered likely to compromise compliance with trial/protocol/31P-MRS acquisition Known claustrophobia or other reasons why patient could not tolerate or be suitable for 31P-MR Spectroscopy (31P-MRS) Current or previous exposure to UDCA Current or previous diagnosis of liver disease judged to be significant by the clinical investigator, in particular Primary Biliary Cholangitis (previously referred to as Primary Biliary Cirrhosis, PBC) Prior intracerebral surgical intervention for PD (including deep-brain stimulation). Patients who have previously undergone deep brain stimulation, intracerebral administration of growth factors, gene therapies or cell therapies will not be eligible Already actively participating in a trial of a device, drug or surgical treatment for PD History of alcoholism Women of child bearing potential (WOCBP) | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Parkinson's Disease PD group： Patients who meet the 2016 China Parkinson's diagnostic and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic Newly diagnosed primary PD patients, diagnosed within 3-6 months Informed consent to the study Age > 18 older Non-PD group Age, gender-matched PD group Non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history Informed consent to the study Age > 18 older Severe craniocerebral trauma patients Disturbance of consciousness Severe organic diseases, cerebral hemorrhage, cerebral thrombosis, severe coronary heart disease and lung disease, severe liver and kidney dysfunction, severe diabetes, severe hearing And visual impairment History of severe brain tumors, encephalitis or brain surgery | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 21.0-85.0, Parkinson Disease Physician-diagnosed Parkinson's disease aged 21-85 years Hoehn & Yahr stage <3 Currently living in the same household with a healthy spouse/partner who meets study and is willing to participate Willing and able to complete informed consent in English Willing to complete daily and weekly questionnaires and 6 dietary recalls over approximately 7 weeks Willing to avoid beer, wine, and cocktails on the day before and the day of the sugar probe tests Willing to provide urine and stool samples during the study collection periods Willing and able to fast (no food or drink, except water or tea) for a prolonged period of time during study urine collections Willing to maintain usual diet through the pre-baseline period Willing to make dietary changes to follow a Mediterranean dietary pattern during the intervention period Does not meet above Atypical or secondary Parkinsonism History of deep brain stimulation Daily use of NSAIDs in the last 3 months or incidental use in the last 2 weeks prior to screening Daily use of anticholinergics or prokinetic agents Use of enemas or suppositories to alleviate constipation Use of another investigational product within 3 months of the screening visit Antibiotic use within 2 months from the day of stool collection Good adherence to the Mediterranean diet during the pre-baseline period (score >6) based on the 14-item Mediterranean Diet Assessment Tool Physician-diagnosed gastrointestinal disease or condition (such as ulcerative colitis, Crohn's disease, gastroparesis, cancer, peptic ulcer disease, Celiac disease, short bowel disease, ileostomy, colostomy) other than gastroesophageal reflux or diverticular disease | 2 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 60.0-999.0, Parkinson Disease Subjects over 60 years of age with a clinical diagnosis of Parkinson's disease Stages of the disease 2-3 of Hoehn and Yahr Not exposed to tobacco during any stage of their life No history of lung diseases No laboratory abnormalities No history of adverse reactions to nicotine Able to use nicotine nasal spray Residents of Mexico City able to attend for evaluations Under current treatment with levodopa at a stable dose Not currently receiving a monoamine oxidase inhibitor treatment Unable to complete follow-up protocol Drug adverse reaction Death | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 21.0-95.0, Parkinson Disease age 21 years or older PD diagnosed by a movement disorder specialist for 3 months or longer prior to recruitment PD medication regimen is stable over the last 3 months with no changes Hoehn & Yahr stage 2 (N = 13) and H&Y stage 3 (N=13) able to walk independently or with a simple assistive device (e.g., cane, walker) observed by the research team to have PD related gait disturbance such as FOG, shortened or irregular stride lengths, irregular step cadence, slowed speed while on their regular treatment regimen diagnosed with a known Parkinson plus syndrome were previously exposed to vibration treatment for gait and balance presence of dementia (Montreal Cognitive Assessment < 21) additional disorders (not related to PD)impairing gait, stance, balance or coordination (e.g. stroke, leg amputations, or multiple sclerosis) history of implantable cardiac device or any other implanted electronic device except a deep brain stimulator (DBS) use of braces/orthotics that assist with walking are currently in physical therapy (PT) treatment for balance or gait peripheral neuropathy by exam any condition that, in the opinion of the PIs, would compromise participant safety, data integrity, or data interpretation Children under the age of 18 | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 50.0-999.0, Parkinson Disease Subjects aged > 50 years, diagnosed as suffering from PD and under follow up of the Movement Disorders Clinic in Soroka University Medical Center Subjects complaining of constipation Subjects who did not perform a screening colonoscopy for colon cancer Subjects who are clinically undertreated according to last Movement Disorders specialist's impression at the clinic visit Subjects who do not complain of constipation or seem clinically stable properly treated pharmacologically Subjects who already underwent a screening colonoscopy for colon cancer Subjects who suffer from a cognitive decline and could not give their consent, or patients who refuse to undergo a colonoscopy | 1 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Syncope Over 18 years Diagnosis of neurally mediated syncope with a tilting table test (Tilt test) that demonstrates a mixed (type 1) or cardioinhibitory response (Type 2A and 2B) Negative impact on work and social life Non-respondent to pharmacological therapy (Fludrocortisone 0.1mg / 24 hours for 3 months) and non-pharmacological (exercise, hydration and consumption of more than 3 months) is due to a cardiologist who has performed a strict stricture over time At least 2 episodes of syncope in the last year Complete atrioventricular block Second degree ventricular atrial block Bradycardia syndrome tachycardia Disease of the sinus node Arrhythmia (bradycardia or tachycardia that generate syncope and / or low cardiac output) Syncope due to hypersensitivity of the carotid sinus Syncope with Tilt Test that demonstrates depressant vasopressor response (type 3) Refusal of the patient, his relatives or the attending physician to participate in the study | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 18.0-999.0, Alcohol Use Disorder Alcohol Dependence Be at least 18 years of age. 2. Have a current (past 12 months) DSM-5 diagnosis of AUD (4 or more symptoms) assessed using the MINI neuropsychiatric interview version 7.0.2 (at least moderate severity, ICD-10-CM Code F10.20 alcohol dependence, uncomplicated). 3. Have a BAC by breathalyzer equal to 0.000 when s/he signed the informed consent document (either just prior to or immediately after signing consent). 4. Be seeking treatment for problems with alcohol reduction in drinking. 5. Be able to verbalize an understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol. 6. Agree (if the subject is female and of child bearing potential) to use at least one of the following methods of birth control, unless she is surgically sterile, partner is surgically sterile or she is postmenopausal: 1. oral contraceptives, 2. contraceptive sponge, 3. patch, 4. double barrier (diaphragm/spermicidal or condom/spermicidal), 5. intrauterine contraceptive system, 6. etonogestrel implant, 7. medroxyprogesterone acetate contraceptive injection, 8. complete abstinence from sexual intercourse, and/or 9. hormonal vaginal contraceptive ring. 7. Be able to take intranasal investigational products and be willing to adhere to the investigational product regimen. 8. Complete all assessments required at screening and baseline. 9. Have a place to live in the 2 weeks prior to randomization and not be at risk that s/he will lose his/her housing by Study Week 14. 10. Not anticipate any significant problems with transportation arrangements or available time to travel to the study site by Study Week 14. 11. Not have any plans to move within Study Week 14 to a location which would make continued participation in the study impractical. 12. Not have any unresolved legal problems that could jeopardize continuation or completion of the study. 13. Provide contact information of someone, such as a family member, spouse, or significant other, who may be able to contact the subject in case of a missed clinic appointment. 14. Be someone who in the opinion of the investigator would be expected to complete the study protocol. 15. Agree to the schedule of visits, verbally acknowledge that s/he will be able to attend each scheduled visit, participate in phone visits and that s/he does not have any already scheduled events or a job that may substantially interfere with study participation. 16. If taking a medication for depression or anxiety, must have been taking a stable dose in the 2-months prior to randomization and plan to continue during the study. This includes drugs such as the following SSRIs Dual uptake inhibitors SNRIs Tricyclic antidepressants MAOIs Bupropion 17. Not currently taking oxytocin and agree not to take non-study oxytocin for the duration of the study Contact study site for | 0 |
The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs. | eligible ages (years): 45.0-75.0, Parkinson's Disease With Cognitive Impairment All patients with Parkinson's Disease who were diagnosed according to UK bank for PD, Aged 45-75 years, with for cognitive impairment (Mini-Mental Status Examination< 24), and consent obtained from the patient or his caregiver History of repeated head injury History of repeated cerebrovascular strokes History of defined encephalitis Oculogyric crisis, supranuclear gaze palsy Family history of more than one relative History of drug intake as antipsychotics or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure Moderate and Severe depression (Hamilton Depression Rating Scale score >16) severe dysautonomia Cerebellar signs Babinski sign | 1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.